Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREVI-OC-01
2025-520466-22-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of AZD5335 in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: authorised.
02
Drugs
AZD5335
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2025-520466-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520466-22-00.